The US Food and Drug Administration (FDA) revoked previous emergency use authorization (EUA) for chloroquine and hydroxychloroquine, two anti-malaria drugs also used to treat chronic rheumatoid arthritis. These drugs have been touted by President Trump as effective treatments for COVID-19. The FDA's release of EUA for the use of chloroquine and hydroxychloroquine in late March drew criticism from many in the medical and pharmaceutical research community, as the evidence seemed mixed in terms of its potential efficacy and risks. It issued a statement of caution about the use of the drug after more cases died in subsequent clinical studies. source